{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T11:29:27Z","timestamp":1780399767774,"version":"3.54.1"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.critrevonc.2025.105039","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T02:50:10Z","timestamp":1763693410000},"page":"105039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Unlocking precision: Bispecific T cell engagers and the next frontier in uro-oncology"],"prefix":"10.1016","volume":"217","author":[{"given":"Joecelyn Kirani","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Vidya Niharika","family":"Gullapalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratima","family":"Chapagain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruni","family":"Ghose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Grollemund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Speechley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Hasanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayali D.","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Advaith","family":"Kandala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akash","family":"Maniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sola","family":"Adeleke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Elena","family":"Rebuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy Yuen-Chun","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y\u00fcksel","family":"\u00dcr\u00fcn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Luigi","family":"Banna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stergios","family":"Boussios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.105039_bib1","unstructured":"American Cancer Society. Cancer Facts & Figures 2024. Atlanta: American Cancer Society; 2024.\u3008https:\/\/www.cancer.org\/cancer\/types\/testicular-cancer\/about\/key-statistics.html\u3009 (Accessed 26 November 2024)."},{"key":"10.1016\/j.critrevonc.2025.105039_bib2","doi-asserted-by":"crossref","first-page":"884","DOI":"10.3390\/ph14090884","article-title":"Research and clinical landscape of bispecific antibodies for the treatment of solid malignancies","volume":"14","author":"Antonarelli","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"17","key":"10.1016\/j.critrevonc.2025.105039_bib3","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.2217\/fon-2016-0155","article-title":"Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises","volume":"12","author":"Aragon-Ching","year":"2016","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2025.105039_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.672262","article-title":"Treating bladder cancer: engineering of current and next generation antibody-, fusion protein-, mRNA-, Cell- and viral-based therapeuics","volume":"11","author":"Bogen","year":"2021","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105039_bib5","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1002\/ijc.28437","article-title":"Comet assay measures of DNA damage are predictive of bladder cancer cell treatment sensitivity in vitro and outcome in vivo","volume":"134","author":"Bowman","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105039_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5092","article-title":"TNB585.001: a multicenter, phase 1, open-label, dose-escalation and expansion study of tnb-585, a bispecific T-cell engager targeting PSMA in subjects with metastatic castrate resistant prostate cancer","volume":"39","author":"Buelow","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105039_bib7","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.105039_bib8","unstructured":"Cancer STAT facts: kidney and renal pelvis cancer. 2022. Available: \u3008www.seer.cancer.gov\/statfacts\/html\/kidrp.html\u3009."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105039_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1158\/0008-5472.CAN-22-1433","article-title":"Immunotherapeutic targeting and PET imaging of DLL3 in small-cell neuroendocrine prostate cancer","volume":"83","author":"Chou","year":"2023","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105039_bib10","doi-asserted-by":"crossref","DOI":"10.4161\/onci.23562","article-title":"Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma","volume":"2","author":"Dannenmann","year":"2013","journal-title":"Oncoimmunology"},{"issue":"20","key":"10.1016\/j.critrevonc.2025.105039_bib11","doi-asserted-by":"crossref","first-page":"6400","DOI":"10.1158\/0008-5472.CAN-11-1261","article-title":"Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway","volume":"71","author":"Daurkin","year":"2011","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105039_bib12","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-20-3725","article-title":"The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer","volume":"27","author":"Deegen","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105039_bib13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.eururo.2016.10.008","article-title":"Global burden of urologic cancers, 1990-2013","volume":"71","author":"Dy","year":"2017","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105039_bib14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-021-01067-5","article-title":"CAR-T cells and BiTEs in solid tumors: challenges and perspectives","volume":"14","author":"Edeline","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2025.105039_bib15","doi-asserted-by":"crossref","first-page":"6852","DOI":"10.1158\/0008-5472.CAN-18-1750","article-title":"An oncolytic virus expressing a T-cell engager simultaneously targets cancer and immunosuppressive stromal cells","volume":"78","author":"Freedman","year":"2018","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105039_bib16","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.15252\/emmm.201707567","article-title":"Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies","volume":"9","author":"Freedman","year":"2017","journal-title":"EMBO Mol. Med"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105039_bib17","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1158\/1535-7163.MCT-12-0042","article-title":"Regression of human prostate cancer xenografts in mice by AMG 212\/BAY2010112, a novel PSMA\/CD3-Bispecific BiTE antibody cross-reactive with non-human primate antigens","volume":"11","author":"Friedrich","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105039_bib18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40425-017-0277-7","article-title":"Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection","volume":"5","author":"Garcia-Carbonero","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105039_bib19","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1158\/1535-7163.MCT-16-0846","article-title":"NKG2D ligand\u2013targeted bispecific T-cell engagers lead to robust antitumor activity against diverse human tumors","volume":"16","author":"Godbersen","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"35","key":"10.1016\/j.critrevonc.2025.105039_bib20","doi-asserted-by":"crossref","first-page":"57964","DOI":"10.18632\/oncotarget.19865","article-title":"CD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1+ tumor cells, and extends the survival of tumor-bearing humanized mice","volume":"8","author":"Horn","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2025.105039_bib21","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105039_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202205532","article-title":"Lipid nanoparticle delivery system for mRNA encoding B7H3-redirected bispecific antibody displays potent antitumor effects on malignant tumors","volume":"10","author":"Huang","year":"2023","journal-title":"Adv. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105039_bib23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/icb.2014.93","article-title":"Bispecific T-cell engagers for cancer immunotherapy","volume":"93","author":"Huehls","year":"2015","journal-title":"Immunol. Cell Biol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105039_bib24","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2217\/imt-2020-0256","article-title":"Pasotuxizumab, a BiTE\u00ae immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings","volume":"13","author":"Hummel","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.critrevonc.2025.105039_bib25","unstructured":"International Agency for Research on Cancer \u3008https:\/\/gco.iarc.fr\/tomorrow\/en\/dataviz\/isotype?cancers=27&single_unit=50000\u3009, Global Cancer Observatory, International Agency for Research on Cancer, 2024, (Accessed on 26 November 2024)."},{"key":"10.1016\/j.critrevonc.2025.105039_bib26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.omto.2022.06.007","article-title":"Development of STEAP1 targeting chimeric antigen receptor for adoptive cell therapy against cancer","volume":"26","author":"Jin","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105039_bib27","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","article-title":"Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2+1 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-human study","volume":"14","author":"Kelly","year":"2024","journal-title":"Cancer Discov."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105039_bib28","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.3390\/cancers17071064","article-title":"Immunotherapy in Prostate Cancer: From a \"Cold\" Tumor to a \"Hot\" Prospect","volume":"17","author":"Kwon","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105039_bib29","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.3390\/cancers17111820","article-title":"T-cell engager therapy in prostate cancer: molecular insights into a new frontier in immunotherapy","volume":"17","author":"Kwon","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.105039_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1399802","article-title":"Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future","volume":"15","author":"Lampe","year":"2024","journal-title":"Front Pharm."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105039_bib31","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.clgc.2023.02.010","article-title":"Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer","volume":"21","author":"Lim","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105039_bib32","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jconrel.2023.01.041","article-title":"Microenvironment-responsive anti-PD-L1 \u00d7 CD3 bispecific T-cell engager for solid tumor immunotherapy","volume":"354","author":"Liu","year":"2023","journal-title":"J. Control Release"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105039_bib33","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.7150\/thno.58390","article-title":"Turning cold tumors into hot tumors by improving T-cell infiltration","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.critrevonc.2025.105039_bib34","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3389\/fonc.2020.01527","article-title":"MEK Inhibitor Augments Antitumor Activity of B7-H3-Redirected Bispecific Antibody","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105039_bib35","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1186\/s12885-020-07562-1","article-title":"A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells","volume":"20","author":"Lund","year":"2020","journal-title":"BMC Cancer"},{"issue":"21","key":"10.1016\/j.critrevonc.2025.105039_bib36","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105039_bib37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40425-019-0510-7","article-title":"A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)","volume":"7","author":"Machiels","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105039_bib38","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.1002\/cam4.1775","article-title":"Targeting immunotherapy for bladder cancer using anti-CD3\u00d7 B7-H3 bispecific antibody","volume":"7","author":"Ma","year":"2018","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105039_bib39","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2159-8290.CD-23-0984","article-title":"AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer","volume":"14","author":"Nolan-Stevaux","year":"2024","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105039_bib40","article-title":"Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma","volume":"12","author":"O'Connell","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105039_bib41","doi-asserted-by":"crossref","first-page":"250","DOI":"10.20517\/2394-4722.2017.41","article-title":"Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead","volume":"3","author":"Oiseth","year":"2017","journal-title":"J. Cancer Metastas.. Treat."},{"key":"10.1016\/j.critrevonc.2025.105039_bib42","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231192402","article-title":"Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer","volume":"15","author":"Parent","year":"2023","journal-title":"Ther. Adv. Med Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105039_bib43","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/cgt.2012.75","article-title":"Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models","volume":"20","author":"Passer","year":"2013","journal-title":"Cancer Gene Ther."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105039_bib44","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1002\/eji.201646898","article-title":"Spontaneous CD4+ and CD8+ T-cell responses directed against cancer testis antigens are present in the peripheral blood of testicular cancer patients","volume":"47","author":"Pearce","year":"2017","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.critrevonc.2025.105039_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1261070","article-title":"Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy","volume":"14","author":"Penny","year":"2023","journal-title":"Front Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105039_bib46","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1158\/2326-6066.CIR-18-0758","article-title":"BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany. The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes","volume":"7","author":"Pfannstiel","year":"2019","journal-title":"Cancer Immunol. Res"},{"key":"10.1016\/j.critrevonc.2025.105039_bib47","doi-asserted-by":"crossref","unstructured":"Elizabeth Pham, Anja Henn, Beate Sable, Joachim Wahl, Kip Conner, Katja Matthes, Shivani Gupta, Rodolfo Yabut, Famke Aeffner, Kristin Lewis Wilson, Jonas Anlahr, Christoph Dahlhoff, Vijay Kale, Matthias Friedrich, Tobias Raum, Peter Kufer, Angela Coxon, Sabine Stienen, Julie M. Bailis. AMG 794, a Claudin 6-targeted half-life extended (HLE) bispecific T cell engager (BITE\u00ae) molecule for non-small cell lung cancer and epithelial ovarian cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5202.","DOI":"10.1158\/1538-7445.AM2022-5202"},{"key":"10.1016\/j.critrevonc.2025.105039_bib48","doi-asserted-by":"crossref","first-page":"461","DOI":"10.3390\/cancers15020461","article-title":"Metastatic Prostate Cancer\u2014A Review of Current Treatment Options and Promising New Approaches","volume":"15","author":"Posdzich","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105039_bib49","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltae008","article-title":"High-affinity T cell receptor ImmTAC\u00ae bispecific efficiently redirects T cells to kill tumor cells expressing the cancer-testis antigen PRAME","volume":"4","author":"Ribeiro","year":"2024","journal-title":"Immunother. Adv."},{"key":"10.1016\/j.critrevonc.2025.105039_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2020.151483","article-title":"Cytoplasmic expression of B7-H3 and membranous EpCAM expression are associated with higher grade and survival outcomes in patients with clear cell renal cell carcinoma","volume":"46","author":"Saeednejad Zanjani","year":"2020","journal-title":"Ann. Diagn. Pathol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105039_bib51","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1080\/17512433.2021.1949287","article-title":"Targeting the spectrum of immune checkpoints in prostate cancer","volume":"14","author":"Sena","year":"2021","journal-title":"Expert Rev. Clin. Pharm."},{"key":"10.1016\/j.critrevonc.2025.105039_bib52","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.3390\/cancers15051412","article-title":"Bispecific T-Cell Engagers Therapies in Solid Tumors: Focusing on Prostate Cancer","volume":"15","author":"Sim\u00e3o","year":"2023","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105039_bib53","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1305535","article-title":"Deep exploration of the immune infiltrate and outcome prediction in testicular cancer by quantitative multiplexed immunohistochemistry and gene expression profiling","volume":"6","author":"Siska","year":"2017","journal-title":"Oncoimmunology"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105039_bib54","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1158\/2159-8290.CD-18-0297","article-title":"CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment","volume":"8","author":"Slaney","year":"2018","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105039_bib55","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1136\/jcp.2011.090274","article-title":"EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis","volume":"64","author":"Spizzo","year":"2011","journal-title":"J. Clin. Pathol."},{"issue":"22","key":"10.1016\/j.critrevonc.2025.105039_bib56","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1200\/JCO-25-00678","article-title":"Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study","volume":"43","author":"Stein","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105039_bib57","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105039_bib58","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","article-title":"Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies","volume":"14","author":"Tian","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105039_bib59","doi-asserted-by":"crossref","unstructured":"Tran B. 1, H.. Kouros-Mehr 2, A.. Fermin 2, L.. Horvath 3, F.. Roncolato 4, M.. Rettig 5, T. Dorff 6, S.T.. Tagawa 7, S.K. Subudhi 8, E.S.. Antonarakis 9, A.J.. Armstrong 10, D.P.. Petrylak 11, K.. Fizazi 12, M.E.. Salvati 2, H.I.. Scher 13 895TiP - A phase I study of AMG 160, a half-life extended bispecific T cell engager (HLE BiTE) immuno-oncology therapy targeting PSMA, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) annalf of oncology. 2019. 30(5): v353 https:\/\/doi.org\/10.1093\/annonc\/mdz248.052.","DOI":"10.1093\/annonc\/mdz248.052"},{"key":"10.1016\/j.critrevonc.2025.105039_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1017574","article-title":"Oncolytic vaccinia virus expressing a bispecific T-cell engager enhances immune responses in EpCAM positive solid tumors","volume":"13","author":"Wei","year":"2022","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2025.105039_bib61","doi-asserted-by":"crossref","first-page":"TPS2669","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS2669","article-title":"A phase I\/II dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of BNT142 in patients with prospectively confirmed claudin 6-positive solid tumors","volume":"41","author":"Yap","year":"2023","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2025.105039_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.696716","article-title":"Immunotherapy in the Treatment of Urothelial Bladder Cancer: Insights From Single-Cell Analysis","volume":"11","author":"Zang","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.105039_bib63","doi-asserted-by":"crossref","DOI":"10.1177\/17562872231182219","article-title":"Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer","volume":"15","author":"Zarrabi","year":"2023","journal-title":"Ther. Adv. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105039_bib64","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3390\/cancers15010100","article-title":"Current Status of Research on Small Extracellular Vesicles for the Diagnosis and Treatment of Urological Tumors","volume":"15","author":"Zhang","year":"2023","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105039_bib65","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3390\/cancers13071724","article-title":"The Tumour Vasculature as a Target to Modulate Leucocyte Trafficking","volume":"13","author":"Zhao","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105039_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100770","article-title":"Efficacy of B7-H3-Redirected BiTE and CAR-T Immunotherapies Against Extranodal Nasal Natural Killer\/T Cell Lymphoma","volume":"13","author":"Zheng","year":"2020","journal-title":"Transl. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105039_bib67","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-024-01792-6","article-title":"A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma","volume":"9","author":"Zhu","year":"2024","journal-title":"Signal Transduct. Target Ther."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004275?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004275?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T19:49:47Z","timestamp":1768333787000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825004275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":67,"alternative-id":["S1040842825004275"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105039","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unlocking precision: Bispecific T cell engagers and the next frontier in uro-oncology","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105039"}}